ISIN | IE00BKWQ0H23 |
---|---|
Valor Number | 24767202 |
Bloomberg Global ID | |
Fund Name | SPDR MSCI Europe Health Care UCITS ETF EUR |
Fund Provider |
State Street Global Advisors
Beethovenstrasse 19, 8002 Zürich E-Mail: Switzerland_ICG_team@ssga.com Web: www.ssga.com spdrsswitzerland@ssga.com (ETF Business) |
Fund Provider | State Street Global Advisors |
Representative in Switzerland |
State Street Bank GmbH, München, Zweigniederlassung Zürich Zürich Phone: +41 44 560 50 00 |
Distributor(s) | State Street Global Advisors |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Ireland |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the Fund is to track the performance of European large and midsized companies in the Health Care sector. |
Peculiarities |
Current Price * | 237.46 EUR | 19.09.2024 |
---|---|---|
Previous Price * | 235.89 EUR | 18.09.2024 |
52 Week High * | 247.60 EUR | 30.08.2024 |
52 Week Low * | 188.77 EUR | 27.10.2023 |
NAV * | 237.46 EUR | 19.09.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 850,886,059 | |
Unit/Share Assets *** | 850,886,059 | |
Trading Information SIX |
YTD Performance | +18.05% |
29.12.2023 - 19.09.2024
29.12.2023 19.09.2024 |
---|---|---|
YTD Performance (in CHF) | +19.58% |
29.12.2023 - 19.09.2024
29.12.2023 19.09.2024 |
1 month | -1.58% |
19.08.2024 - 19.09.2024
19.08.2024 19.09.2024 |
3 months | +2.66% |
19.06.2024 - 19.09.2024
19.06.2024 19.09.2024 |
6 months | +10.73% |
19.03.2024 - 19.09.2024
19.03.2024 19.09.2024 |
1 year | +16.61% |
19.09.2023 - 19.09.2024
19.09.2023 19.09.2024 |
2 years | +33.87% |
19.09.2022 - 19.09.2024
19.09.2022 19.09.2024 |
3 years | +32.15% |
20.09.2021 - 19.09.2024
20.09.2021 19.09.2024 |
5 years | +63.30% |
19.09.2019 - 19.09.2024
19.09.2019 19.09.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Novo Nordisk A/S Class B | 23.12% | |
---|---|---|
AstraZeneca PLC | 13.77% | |
Roche Holding AG | 12.10% | |
Novartis AG Registered Shares | 12.07% | |
Sanofi SA | 6.50% | |
GSK PLC | 4.59% | |
Essilorluxottica | 3.55% | |
Lonza Group Ltd | 2.48% | |
Alcon Inc | 2.47% | |
argenx SE | 1.57% | |
Last data update | 31.08.2024 |
TER *** | 0.18% |
---|---|
TER date *** | 31.03.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.18% |
Ongoing Charges *** | 0.18% |
SRRI ***
|
|
SRRI date *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |